Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Economic Times
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing…
Summary from Economic Times
Read the full story on Economic Times
